FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Dec. 31, 2013

Fair Value Disclosures [Abstract]

Schedule Of Financial Assets And Liabilities

The following tables present the Company’s financial assets and liabilities measured on a recurring basis using the fair value hierarchy as of December 31, 2013 and March 31, 2013 (in thousands).

	Fair Value Measurements at
	December 31, 2013
	Level 1		Level 2			Level 3			Total
ASSETS:
Cash and cash equivalents	$	88,648	$	0		$	0		$	88,648
U.S. government and municipal obligations	74,603		0			0			74,603
Commercial paper	0		7,093			0			7,093
Corporate bonds	9,810		0			0			9,810
Certificate of deposits	0		2,059			0			2,059
Derivative financial instruments	0		367			0			367
	$	173,061	$	9,519		$	0		$	182,580
LIABILITIES:
Contingent purchase consideration	$	0	$	0		$	(4,219	)	$	(4,219	)
Contingent contractual non-compliance liability	0		0			(98		)	(98		)
Derivative financial instruments	0		(138		)	0			(138		)
	$	0	$	(138	)	$	(4,317	)	$	(4,455	)

	Fair Value Measurements at
	March 31, 2013
	Level 1		Level 2			Level 3			Total
ASSETS:
Cash and cash equivalents	$	99,930	$	0		$	0		$	99,930
U.S. government and municipal obligations	31,645		0			0			31,645
Commercial paper	0		12,390			0			12,390
Corporate bonds	5,166		0			0			5,166
Certificate of deposits	0		4,960			0			4,960
Derivative financial instruments	0		71			0			71
	$	136,741	$	17,421		$	0		$	154,162
LIABILITIES:
Contingent purchase consideration	$	0	$	0		$	(5,087	)	$	(5,087	)
Contingent contractual non-compliance liability	0		0			(246		)	(246		)
Derivative financial instruments	0		(249		)	0			(249		)
	$	0	$	(249	)	$	(5,333	)	$	(5,582	)

Reconciliation Of Changes In Fair Value Of Level III Financial Assets

The following table sets forth a reconciliation of changes in the fair value of the Company’s Level 3 financial liabilities for the nine months ended December 31, 2013 (in thousands):

	Contingent Purchase Consideration			Contingent Contractual Non-compliance Liability
Balance at beginning of period	$	(5,087	)	$	(246	)
Change in fair value (included within research and development expense)	27			148
Payments	841			0
Balance at end of period	$	(4,219	)	$	(98	)